Clinical Trials Browser

Phase 2 × Active not recruiting × Recurrence × Clear all

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

Melanoma, Recurrence

NCT04842877 2026-02-19

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05144841 2026-02-13

MK-2140-004

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06105632 2026-02-13

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 2 Active not recruiting

Breast Neoplasms, Recurrence

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT06485219 2026-02-06

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Phase 2 Active not recruiting

DermatologicLymphoid

Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05460533 2026-02-04

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Active not recruiting

Burkitt Lymphoma, Recurrence

NCT05043922 2026-01-30

A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma

Phase 2 Active not recruiting

Ovarian Neoplasms, Recurrence

NCT05797246 2026-01-26

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

Phase 2 Active not recruiting

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05199051 2026-01-05

AGORA-1

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Phase 2 Active not recruiting

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02151084 2025-12-16

A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer

Phase 2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Recurrence

NCT06253663 2025-12-16

JKART-1

Phase 2 Active not recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT03999710 2025-11-28

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Recurrence

NCT03734198 2025-11-26

IDA53

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05704829 2025-11-19

ADAPTHER2-IV

Phase 2 Active not recruiting

Recurrence

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

Phase 2 Active not recruiting

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT04245839 2025-11-05

TRANSCEND FL

Phase 2 Active not recruiting

276 enrolled 2 FDA

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT03355976 2025-10-09

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT05064358 2025-10-07

DREAMM 14

Phase 2 Active not recruiting

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT05498220 2025-09-02

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05020015 2025-08-12

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2 Active not recruiting

27 enrolled 23 charts

Recurrence, Lymphoma, B-Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03179930 2025-07-23

Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Phase 2 Active not recruiting

Lymphoma, Recurrence

NCT00544115 2025-06-10

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Phase 2 Active not recruiting

260 enrolled 13 charts

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellSarcoma

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Graft vs Host Disease, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Precancerous Conditions, Recurrence, Sezary Syndrome, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT05451810 2025-01-24

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Phase 2 Active not recruiting

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03634540 2024-12-20

MK-6482-003

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03385226 2024-12-09

PORT

Phase 2 Active not recruiting

DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02406222 2024-12-05

MUKseven

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT04713514 2024-12-02

TEDOVA

Phase 2 Active not recruiting

Ovarian Neoplasms, Recurrence

NCT02203760 2024-11-15

PazoDoble

Phase 2 Active not recruiting

Carcinosarcoma, Leiomyosarcoma, Recurrence

NCT06149169 2024-08-21

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03374332 2024-02-08

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Phase 2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute, Disease Progression

NCT04718883 2023-11-24

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Mantle-Cell